Urooj Fatima1, Safi U Khan2, Olabisi Akanbi3, Saket Girotra4, Isaac Opoku-Asare3. 1. Howard University Hospital, United States of America. Electronic address: ufatima@huhosp.org. 2. West Virginia University, United States of America. 3. Howard University Hospital, United States of America. 4. University of Iowa Hospitals and Clinics, United States of America.
Abstract
BACKGROUND: In patients with ST elevation myocardial infarction (STEMI) and concomitant multi-vessel disease (MVD), primary percutaneous coronary intervention (PCI) of the culprit vessel is the preferred reperfusion strategy. However, optimum timing of revascularization for non-culprit artery is unclear. In this Bayesian network meta-analysis (NMA), we compared different PCI-based revascularization strategies in STEMI patients with MVD. METHODS: 11 randomized controlled trials (RCTs) were selected using MEDLINE, EMBASE and CENTRAL (Inception to September 2017). For all outcomes, median estimate of odds ratio from posterior distribution with corresponding 95% credible interval was calculated. The Surface under the Cumulative Ranking Curve (SUCRA) metric was used to estimate the relative ranking probability of each intervention. Sensitivity analysis was conducted by excluding the RCTs in which the staged intervention was performed after two weeks of the index procedure or post discharge. RESULTS: In this NMA of 3172 patients, CR-I (instant complete revascularization) was associated with 40% relative risk reduction in all-cause mortality compared with IRA (infarct related artery) [0.60 (0.31-0.89)]. CR-I was superior to CR-S (staged complete revascularization) [0.42 (0.22-0.70)] and IRA [0.50(0.29-0.72)] in reducing the risk of re- infarction. Both CR-I and CR-S significantly reduced the risk of repeat revascularization compared to IRA, whereas the risk of CIN (contrast induced nephropathy) and major bleeding was similar across all interventions. Sensitivity analysis showed, that CR-I was a better strategy compared with CR-S [0.34 (0.12-0.74)] and IRA (0.60 [0.36-0.97]) in reducing all-cause mortality. CONCLUSIONS: In this NMA, CR-I was associated with reduction in all-cause mortality and re- infarction compared with IRA.
BACKGROUND: In patients with ST elevation myocardial infarction (STEMI) and concomitant multi-vessel disease (MVD), primary percutaneous coronary intervention (PCI) of the culprit vessel is the preferred reperfusion strategy. However, optimum timing of revascularization for non-culprit artery is unclear. In this Bayesian network meta-analysis (NMA), we compared different PCI-based revascularization strategies in STEMI patients with MVD. METHODS: 11 randomized controlled trials (RCTs) were selected using MEDLINE, EMBASE and CENTRAL (Inception to September 2017). For all outcomes, median estimate of odds ratio from posterior distribution with corresponding 95% credible interval was calculated. The Surface under the Cumulative Ranking Curve (SUCRA) metric was used to estimate the relative ranking probability of each intervention. Sensitivity analysis was conducted by excluding the RCTs in which the staged intervention was performed after two weeks of the index procedure or post discharge. RESULTS: In this NMA of 3172 patients, CR-I (instant complete revascularization) was associated with 40% relative risk reduction in all-cause mortality compared with IRA (infarct related artery) [0.60 (0.31-0.89)]. CR-I was superior to CR-S (staged complete revascularization) [0.42 (0.22-0.70)] and IRA [0.50(0.29-0.72)] in reducing the risk of re- infarction. Both CR-I and CR-S significantly reduced the risk of repeat revascularization compared to IRA, whereas the risk of CIN (contrast induced nephropathy) and major bleeding was similar across all interventions. Sensitivity analysis showed, that CR-I was a better strategy compared with CR-S [0.34 (0.12-0.74)] and IRA (0.60 [0.36-0.97]) in reducing all-cause mortality. CONCLUSIONS: In this NMA, CR-I was associated with reduction in all-cause mortality and re- infarction compared with IRA.
Authors: Andrzej Ochala; Grzegorz A Smolka; Wojciech Wojakowski; Dariusz Dudek; Artur Dziewierz; Zbigniew Krolikowski; Zbigniew Gasior; Michal Tendera Journal: J Invasive Cardiol Date: 2004-12 Impact factor: 2.022
Authors: Stephen D Wiviott; Eugene Braunwald; Carolyn H McCabe; Gilles Montalescot; Witold Ruzyllo; Shmuel Gottlieb; Franz-Joseph Neumann; Diego Ardissino; Stefano De Servi; Sabina A Murphy; Jeffrey Riesmeyer; Govinda Weerakkody; C Michael Gibson; Elliott M Antman Journal: N Engl J Med Date: 2007-11-04 Impact factor: 91.245
Authors: Laura Mauri; Treacy S Silbaugh; Pallav Garg; Robert E Wolf; Katya Zelevinsky; Ann Lovett; Manu R Varma; Zheng Zhou; Sharon-Lise T Normand Journal: N Engl J Med Date: 2008-09-25 Impact factor: 91.245
Authors: Lars Wallentin; Richard C Becker; Andrzej Budaj; Christopher P Cannon; Håkan Emanuelsson; Claes Held; Jay Horrow; Steen Husted; Stefan James; Hugo Katus; Kenneth W Mahaffey; Benjamin M Scirica; Allan Skene; Philippe Gabriel Steg; Robert F Storey; Robert A Harrington; Anneli Freij; Mona Thorsén Journal: N Engl J Med Date: 2009-08-30 Impact factor: 91.245
Authors: Paul Sorajja; Bernard J Gersh; David A Cox; Michael G McLaughlin; Peter Zimetbaum; Costantino Costantini; Thomas Stuckey; James E Tcheng; Roxana Mehran; Alexandra J Lansky; Cindy L Grines; Gregg W Stone Journal: Eur Heart J Date: 2007-06-07 Impact factor: 29.983
Authors: A E Ades; Mark Sculpher; Alex Sutton; Keith Abrams; Nicola Cooper; Nicky Welton; Guobing Lu Journal: Pharmacoeconomics Date: 2006 Impact factor: 4.981